Abstract:Introduction Structural and functional impairments of cerebral small vessels (CSVs) result in white matter hypo‐perfusion and ischemia that are major cause of Cerebral small vessel disease (CSVD) or white matter disease is a variety of abnormalities in brain microvasculature. Recently, chronic kidney disease (CKD) has been identified as a significant risk factor for stroke as well as for subclinical vascular diseases such as CSVD. Endothelial cell dysfunction is a major contributor to CSVD in CKD. Interestingly, both kidney and cerebral microvasculature share similar anatomical and physiologic characteristics. The goal of this study was to elucidate the molecular mechanisms of hyperphosphatemia in cerebral microvasculature using human brain microvascular endothelial cells (HBMECs), human arteries, and CKD mice as our models. Methods CKD mice model was generated by 5/6 nephrectomy on 8‐week‐old C57BL/6 mice. Mice were sacrificed at four months after 5/6 nephrectomy. And, we performed transcriptome analysis by RNA sequencing in primary human brain microvascular endothelial cells (HBMECs) that were treated in calcification medium (CM: 5mM β‐glycerolphosphate and 5mM CaCl2) in time‐course experiments (0–48 hours), in vitro ; and human arteries, ex vivo from healthy and CKD patients. Gene selections were performed by the combinations of fold‐changes on log 2 ratio, and p value < 0.05. Results Our results showed that CKD mice had decreased myelinated nerve fibers in the corpus callosum and cerebral cortex and loosening myelinated fibers in the corpus callosum. We found collagen IV accumulation in brain microvasculature, a pattern associated with aging. Serum phosphate levels were significant increased in CKD mice compared to control mice. In primary HBMECs treated with CM, we found that major transmembrane tight junction (TJ) protein Occludin was upregulated at 6 hours and peaked at 48 hours. Inflammation sensitive transmembrane TJ protein, Claudin‐5 increased at 1 hour followed by upregulation of downstream ZO‐1 at 6 hours. In human CKD arteries, we found that claudin‐5 was downregulated (Fold changes, FC, 2.16) while ZO‐1 was upregulated (FC=2.17). Furthermore, cell viability decreased and caspase‐3 mediated apoptosis increased in CM treated HBMEC. In addition, Collagen IV expression increased in a dose‐dependent manner at 72 hours after CM treated HBMECs. Conclusion Our data show for the first time that cerebral white matter and microvascular dysfunction occurs in uremic environments in CKD, in vitro and in vivo . In addition, our data indicates that TJ dysfunction in brain microvasculature is an important pathogenic process in the development of uremic‐related cardiovascular disease and CSVD. Our data provides a potential mechanism for the development of CSVD in CKD patients. It could benefit CKD patients to reduce the following CSVD and dementia through controlling blood phosphate levels and maintain TJ's function. This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .

Microglial activation in CKD-associated cognitive decline

Chronic kidney disease leads to microglial potassium efflux and inflammasome activation in the brain

[Cognitive impairment and the blood-brain barrier in chronic kidney disease: role of the uremic toxins]

MICROGLIAL ACTIVATION BY THE BRAIN RENIN‐ANGIOTENSIN SYSTEM

Abstract 87: Chronic Kidney Disease Induces Cerebral Microhemorrhages In Aged Mice

Abstract 208: Action of Multifaceted Microglia on Blood Pressure Control

Reduced Hippocampal Neuronal Activity and Impaired Cognitive Function in a Mouse Model of Chronic Kidney Disease

Mechanisms of cognitive dysfunction in CKD

Increased Blood-Brain Barrier Permeability and Cognitive Impairment in Patients With ESKD

Chronic Kidney Disease and Cognitive Impairment: The Kidney-Brain Axis

Kidney–brain crosstalk in the acute and chronic setting

Emotional and cognitive changes in chronic kidney disease

Chronic kidney disease causes blood-brain barrier breakdown via urea-activated matrix metalloproteinase-2 and insolubility of tau protein

Cognitive Impairment in CKD: Pathophysiology, Management, and Prevention

Kidney-brain axis in the pathogenesis of cognitive impairment

Effect of glymphatic system function on cognitive function in patients with chronic kidney disease

Acute Kidney Injury, Systemic Inflammation, and Long-Term Cognitive Function: ASSESS-AKI

Abstract TP292: Chronic Kidney Disease Exacerbates Post-Stroke Cell Death and Inflammatory Mechanisms

Association of Proximal Tubular Secretory Clearance with Long-Term Decline in Cognitive Function

The molecular mechanisms of chronic kidney disease induced hyperphosphatemia in cerebral microvasculature

Uremic Toxic Blood-Brain Barrier Disruption Mediated by AhR Activation Leads to Cognitive Impairment during Experimental Renal Dysfunction